Physician profile
Robert E Stevens
NPI 1689767105
$6,944.40
in general payments reported to CMS, 2019-2025
20 companies · $1,976 in 2025
The $1,976 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $657 · 2022: $1,264 · 2023: $1,299 · 2024: $1,749 · 2025: $1,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,920 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,919.55 |
| Education | $103.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,355.76 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $957.52 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $942.90 | 2021-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $900.30 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $725.49 | 2021-2025 | |
| Genzyme Corporation | $526.51 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $335.03 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $270.90 | 2023-2025 | Adbry, Anzupgo |
| Ucb, INC. | $245.93 | 2021-2025 | Bimzelx, Cimzia |
| Kyowa Kirin, INC. | $136.99 | 2021-2025 | Poteligeo |
| Regeneron Healthcare Solutions, INC. | $95.28 | 2021-2025 | Libtayo, Dupixent |
| Organogenesis INC. | $94.01 | 2023-2024 | Affinity, Puraply |
| Amgen INC. | $86.47 | 2024-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $80.11 | 2023-2024 | Siliq |
| Mayne Pharma Commercial LLC | $55.65 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $50.74 | 2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.23 | 2023-2024 | Spevigo |
| Pfizer INC. | $25.40 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $16.33 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.85 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.